CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
CTMX Interest Income
Income earned on cash, deposits, and investments held by the company.
CytomX Therapeutics, Inc.NASDAQ: CTMX
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income growth accelerates
Q1 FY2026 interest income of $1.49M rose 56.0% year over year, ahead of the -2.6% change in trailing-twelve-month interest income. Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +45.8% a year.
Context
- Interest income amounted to 6.8% of revenue in FY2025, up 1.7 pp from a year earlier.
- Interest income increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +56.0% holds above the trailing-twelve-month pace of -2.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 5.21M USD
- Year-over-year change
- -27.0%
- 4-year CAGR
- +112.6%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.21M | -27.0% |
| FY2024 | 2024-12-31 | 7.14M | -27.5% |
| FY2023 | 2023-12-31 | 9.84M | +486.2% |
| FY2022 | 2022-12-31 | 1.68M | +558.0% |
| FY2021 | 2021-12-31 | 255K | — |
Interest Income vs competitors
How CTMX compares with its peers on the latest reported figures
- CTMX's LTM Mar 2026 interest income of $5.74M is the 9th highest of the 10 companies compared; the peer median is $8.75M.
- Its year-over-year change of -2.6% is the highest of 9, against a peer median of -23.8%.
- Interest income amounts to 16.2% of revenue for CTMX, versus a peer median of 11.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $25.4M | -19.9% | +114.3% | 22679.5% | |
| LTM Jun 2026 | $23M | -24.6% | +78.8% | 21.9% | |
| LTM Aug 2026 | $18.56M | -20.1% | +84.3% | 2.6% | |
| LTM Sep 2026 | $11.45M | -20.8% | +54.9% | 4.3% | |
| LTM Mar 2026 | $8.75M | -23.1% | +50.8% | 11.1% | |
| LTM Mar 2026 | $7.7M | -80.3% | +38.9% | 7.7% | |
| LTM Jun 2024 | $6.08M | — | +82.7% | 745.4% | |
| LTM Mar 2026 | $5.93M | -29.4% | +26.0% | 3.8% | |
| LTM Mar 2026 | $5.74M | -2.6% | +45.8% | 16.2% | |
| LTM Mar 2026 | $2.83M | -58.0% | +9.3% | 20.4% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CTMX) | $8.75M | -23.8% | +54.9% | 11.1% | |
Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 114.19M | 111.65M | 77.68M | 83.38M | 68.73M |
| Selling, General & Admin | 39.16M | 42.85M | 30.02M | 29.73M | 29.84M |
| Operating Expenses | 153.35M | 154.5M | 107.7M | 113.11M | 98.57M |
| Depreciation & Amortization | 2.71M | 2.44M | 2.18M | 1.77M | 1.38M |
| EBITDA | (113.16M) | (96.87M) | 5.5M | 33.86M | (15.75M) |
| EBITDA Margin | -303.3% | -182.2% | 5.4% | 24.5% | -20.7% |
| Operating Income | (116.04M) | (101.34M) | (6.48M) | 25M | (22.36M) |
| Operating Margin | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Interest Income | 255K | 1.68M | 9.84M | 7.14M | 5.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 172K | 2.02M | 9.81M | 7.1M | 5.23M |
| Income Before Tax | (115.87M) | (99.32M) | 3.32M | 32.09M | (17.13M) |
| Pre-Tax Margin | -310.5% | -186.8% | 3.3% | 23.2% | -22.5% |
| Income Tax Expense | 0 | 0 | 3.89M | 224K | 238K |
| Net Income | (115.87M) | (99.32M) | (569K) | 31.87M | (17.37M) |
| Net Margin | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| EPS (Basic) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| EPS (Diluted) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| Weighted Avg Shares | 64.15M | 65.74M | 73.81M | 84.44M | 137.94M |
| Weighted Avg Shares (Diluted) | 64.15M | 65.74M | 73.81M | 84.75M | 137.94M |
CytomX Therapeutics, Inc.
NASDAQ:CTMX
Intrinsic Alpha fair value
Locked
Current Price
$1.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.